Update About Oralair® As a Treatment for Grass Pollen Allergic Rhinitis

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Jun 15

PMID 35704772

Authors

L Klimek

R Brehler

R Mosges

P Demoly

J Mullol

D Y Wang

R E OHehir

A Didier

M Kopp

C Bos

E Karagiannis

Affiliations

Soon will be listed here.

Abstract

Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.

Citing Articles

The Melbourne epidemic thunderstorm asthma event 2016: a 5-year longitudinal study.

Huang F, Wang D, Foo C, Young A, Fok J, Thien F Asia Pac Allergy. 2022; 12(4):e38.

PMID: 36452015 PMC: 9669468. DOI: 10.5415/apallergy.2022.12.e38.

References

Verheggen B, Westerhout K, Schreder C, Augustin M . Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy. 2015; 5:1. PMC: 4330981. DOI: 10.1186/s13601-015-0045-z. View

Calderon M, Waserman S, Bernstein D, Demoly P, Douglass J, Gagnon R . Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. J Allergy Clin Immunol Pract. 2020; 8(9):2920-2936.e1. DOI: 10.1016/j.jaip.2020.04.071. View

Pfaar O, Richter H, Klimek L, Sieber J, Hadler M, Karagiannis E . Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study. Biomed Res Int. 2015; 2015:584291. PMC: 4553179. DOI: 10.1155/2015/584291. View

Chabre H, Gouyon B, Huet A, Baron-Bodo V, Boran-Bodo V, Nony E . Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy. 2009; 40(3):505-19. DOI: 10.1111/j.1365-2222.2009.03380.x. View

Didier A, Bons B . Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opin Drug Saf. 2015; 14(5):777-88. DOI: 10.1517/14740338.2015.1017468. View

Didier A, Wahn U, Horak F, Cox L . Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014; 10(10):1309-24. DOI: 10.1586/1744666X.2014.957677. View

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

Heeringa J, McKenzie C, Varese N, Hew M, Bakx A, Aui P . Induction of IgG and IgG B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy. 2019; 75(5):1121-1132. PMC: 7317934. DOI: 10.1111/all.14073. View

Malling H, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E . Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009; 39(3):387-93. PMC: 4233960. DOI: 10.1111/j.1365-2222.2008.03152.x. View

10.

Cox L, Murphey A, Hankin C . The Cost-Effectiveness of Allergen Immunotherapy Compared with Pharmacotherapy for Treatment of Allergic Rhinitis and Asthma. Immunol Allergy Clin North Am. 2019; 40(1):69-85. DOI: 10.1016/j.iac.2019.09.003. View

11.

Roberts G, Pfaar O, Akdis C, Ansotegui I, Durham S, Gerth van Wijk R . EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2017; 73(4):765-798. DOI: 10.1111/all.13317. View

12.

Blaiss M, Hammerby E, Robinson S, Kennedy-Martin T, Buchs S . The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review. Ann Allergy Asthma Immunol. 2018; 121(1):43-52.e3. DOI: 10.1016/j.anai.2018.03.028. View

13.

Batard T, Sanjuan A, Denis L, Nguyen H, Montagut A, Sastre J . Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires. Clin Transl Allergy. 2019; 9:13. PMC: 6391756. DOI: 10.1186/s13601-019-0253-z. View

14.

van Nunen S, Burk M, Burton P, Ford G, Harvey R, Lozynsky A . 5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen. World Allergy Organ J. 2022; 15(2):100632. PMC: 8873945. DOI: 10.1016/j.waojou.2022.100632. View

15.

Shah-Hosseini K, Krudewig E, Hadler M, Karagiannis E, Mosges R . Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study. Adv Ther. 2017; 34(6):1382-1397. PMC: 5487874. DOI: 10.1007/s12325-017-0535-6. View

16.

Thien F, Beggs P, Csutoros D, Darvall J, Hew M, Davies J . The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health. 2018; 2(6):e255-e263. DOI: 10.1016/S2542-5196(18)30120-7. View

17.

Pfaar O, Lou H, Zhang Y, Klimek L, Zhang L . Recent developments and highlights in allergen immunotherapy. Allergy. 2018; 73(12):2274-2289. DOI: 10.1111/all.13652. View

18.

Ras L, de Groot H, Stengs C, van Weissenbruch R . Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study. Ann Allergy Asthma Immunol. 2015; 116(1):52-58.e2. DOI: 10.1016/j.anai.2015.10.018. View

19.

Ciprandi G, Incorvaia C, Frati F . Management of polysensitized patient: from molecular diagnostics to biomolecular immunotherapy. Expert Rev Clin Immunol. 2015; 11(9):973-6. DOI: 10.1586/1744666X.2015.1062365. View

20.

Moingeon P . Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2014; 1(3):228-41. DOI: 10.1016/j.jaip.2013.03.013. View